1. 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. (September 2015) Authors: Fontaniere, C. De La Fouchardiere; Paule, B.; Burtin, P; Wallet, J.; Tougeron, D.; Dourthe, L.M.; Etienne, P.L.; Mineur, L.; Becuwe, C.; Maes, P.; Dauba, J.; Michel, P.; Wendling, J.L.; Linot, B.; Hollebecque, A.; Clisant, S.; Morere, J.F.; Andre, T.; Phelip, J.M.; Adenis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S360 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗